CMB International Maintains SINO BIOPHARM (01177) Target Price at HK$9.4 with "Buy" Rating

Stock News

Oct 13

CMB International has released a research report maintaining SINO BIOPHARM's (01177) target price at HK$9.4 and "Buy" rating based on a DCF model. The firm projects the group's revenue growth rates for 2025-2027 at 19.1%, 4.4%, and 10.6% respectively.

The firm also forecasts adjusted net profit growth of 81.3% for 2025 and 11.3% for 2027, while expecting a 30% decline in 2026. The projections do not yet account for potential contributions from out-licensing deals to revenue and profits.

SINO BIOPHARM recently announced Phase II clinical results for its PDE3/4 inhibitor TQC3721. The clinical data demonstrated that TQC3721 can rapidly improve patients' lung function and symptoms. The firm believes TQC3721 has the potential to become a blockbuster drug with significant out-licensing opportunities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127697271"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127697271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127697271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127697271","market":"sh","top_or_hot":-1,"title":"CMB International Maintains SINO BIOPHARM (01177) Target Price at HK$9.4 with \"Buy\" Rating","media":"Stock News","content":"<p>CMB International has released a research report maintaining SINO BIOPHARM's (01177) target price at HK$9.4 and \"Buy\" rating based on a DCF model. The firm projects the group's revenue growth rates for 2025-2027 at 19.1%, 4.4%, and 10.6% respectively.</p>\n<p>The firm also forecasts adjusted net profit growth of 81.3% for 2025 and 11.3% for 2027, while expecting a 30% decline in 2026. The projections do not yet account for potential contributions from out-licensing deals to revenue and profits.</p>\n<p>SINO BIOPHARM recently announced Phase II clinical results for its PDE3/4 inhibitor TQC3721. The clinical data demonstrated that TQC3721 can rapidly improve patients' lung function and symptoms. The firm believes TQC3721 has the potential to become a blockbuster drug with significant out-licensing opportunities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMB International Maintains SINO BIOPHARM (01177) Target Price at HK$9.4 with \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMB International Maintains SINO BIOPHARM (01177) Target Price at HK$9.4 with \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-13 10:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMB International has released a research report maintaining SINO BIOPHARM's (01177) target price at HK$9.4 and \"Buy\" rating based on a DCF model. The firm projects the group's revenue growth rates for 2025-2027 at 19.1%, 4.4%, and 10.6% respectively.</p>\n<p>The firm also forecasts adjusted net profit growth of 81.3% for 2025 and 11.3% for 2027, while expecting a 30% decline in 2026. The projections do not yet account for potential contributions from out-licensing deals to revenue and profits.</p>\n<p>SINO BIOPHARM recently announced Phase II clinical results for its PDE3/4 inhibitor TQC3721. The clinical data demonstrated that TQC3721 can rapidly improve patients' lung function and symptoms. The firm believes TQC3721 has the potential to become a blockbuster drug with significant out-licensing opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YR35.GBP","symbol_name":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","start_time":0,"source_url":"","article_id":"1127697271","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127697271","pubTimestamp":1760321061,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMB International has released a research report maintaining SINO BIOPHARM's (01177) target price at HK$9.4 and \"Buy\" rating based on a DCF model. The firm projects the group's revenue growth rates...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","01177":"中国生物制药"},"translate_title":"招银国际维持中国生物医药(01177)目标价9.4港元“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"CMB International has released a research report maintaining SINO BIOPHARM's (01177) target price at HK$9.4 and \"Buy\" rating based on a DCF model. The firm projects the group's revenue growth rates for 2025-2027 at 19.1%, 4.4%, and 10.6% respectively.\nThe firm also forecasts adjusted net profit growth of 81.3% for 2025 and 11.3% for 2027, while expecting a 30% decline in 2026. The projections do not yet account for potential contributions from out-licensing deals to revenue and profits.\nSINO BIOPHARM recently announced Phase II clinical results for its PDE3/4 inhibitor TQC3721. The clinical data demonstrated that TQC3721 can rapidly improve patients' lung function and symptoms. The firm believes TQC3721 has the potential to become a blockbuster drug with significant out-licensing opportunities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}